SCHEMBL8370910

SCHEMBL8370910

Cc1ccc2ccc(Br)cc2c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.52
CYP1A2 P05177 3/20 0.52
TSHR P16473 1/20 0.52
TYMS P04818 2/20 0.41
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
PLG P00747 1/20 0.36
PLAU P00749 1/20 0.36
PLAT P00750 1/20 0.36
MAPK1 P28482 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
CASP3 P42574 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19798970 0.84 CYP2A6 (0.50) CYP2A6CYP1A2TSHRALDH1A1KDM4E
SCHEMBL6042452 0.82 TYMS (0.41) CYP2A6CYP1A2TYMSALDH1A1KDM4E
SCHEMBL6041439 0.82 TYMS (0.41) CYP2A6CYP1A2TSHRTYMSALDH1A1
SCHEMBL38662570 0.81 CYP2A6 (0.42) CYP2A6CYP1A2TYMSALDH1A1KDM4E
SCHEMBL24150000 0.78 KDM4E (0.52) CYP2A6TYMSALDH1A1KDM4EMEN1
SCHEMBL8345784 0.78 TYMS (0.39) CYP2A6CYP1A2TSHRTYMSALDH1A1
SCHEMBL15412757 0.78 CYP1A2 (0.56) CYP2A6CYP1A2TSHRALDH1A1KDM4E
SCHEMBL29595200 0.77 CYP2A6 (0.52) CYP2A6CYP1A2TYMSALDH1A1KDM4E
SCHEMBL1569370 0.77 CYP2A6 (0.52) CYP2A6CYP1A2TYMSALDH1A1KDM4E
SCHEMBL30518173 0.76 CYP1A2 (0.58) CYP2A6CYP1A2TSHRTYMSALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1142928-C Synthesis and use of retinoid compounds having negative hormone and/or antagonist activity �ո��� 2004-03-24 CN disclosed
CN-1121379-C Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 2003-09-17 CN disclosed
CN-1360890-A Use of active retiene derivative with negative hormone and/or antagonist ALLERGAN INC (US) 2002-07-31 CN disclosed
CN-1268130-A Synthesis and use of retinol derivative compounds having negative hormone and/or antagonist activity ALLERGAN SALES INC (US) 2000-09-27 CN disclosed
EP-0948478-A1 ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO 1,2-g]-CHROM-3-ENE, BENZO 1,2-g]-THIOCHROM-3-ENE AND BENZO 1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY Allergan Sales, Inc. (US) 1999-10-13 EP disclosed
CN-1209802-A Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 1999-03-03 CN disclosed
WO-1998025875-A1 ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY ALLERGAN SALES, INC. (US) 1998-06-18 WO disclosed